Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine

Acta Tropica

Volumn 70, Issue 3, 1998, Pages 317-333

  Lang, J ^a   Attanath, P ^b   Quiambao, B ^c   Singhasivanon, V ^b   Chanthavanich, P ^b   Montalban, C ^c   Lutsch, C ^a   Pepin Covatta, S ^d   Le Mener, V ^a   Miranda, M ^c   Sabchareon, A ^b  

^a Med Dept Pasteur Merieux C   (France)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Department of Health   (Philippines)

^d HÔPITAL FERNAND WIDAL   (France)

Author keywords

Equine rabies immunoglobulin; Heat treated; Pharmacokinetic; Post exposure treatment; Purified; Safety; Vero cell rabies vaccine

Indexed keywords

FAVIRAB; IMMUNOGLOBULIN F(AB')2 FRAGMENT; PASTEUR ANTIRABIES SERUM; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PAIN; PARESTHESIA; PHILIPPINES; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; THAILAND; VERTIGO;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CERCOPITHECUS AETHIOPS; DOUBLE-BLIND METHOD; HORSES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; PHILIPPINES; PROSPECTIVE STUDIES; RABBITS; RABIES; RABIES VACCINES; RABIES VIRUS; REGRESSION ANALYSIS; THAILAND; VERO CELLS;

EID: 0032581571     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(98)00038-2     Document Type: Article

References (22)

1. Bahmanyar, M., Fayaz, A., Nour-Salehi, S., Mohammadi, M., Koprowski, H., 1976. Post-exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. J. Am. Med. Assoc. 236, 2751-2754.
2. Baltazard, M., Bahmanyar, M., 1955. Essai pratique du sérum antirabique chez les mordus par loups enragés. Bull. Org. Mond. Santé 13, 747-772.
3. Bhanganada, K., Wilde, H., Sakolsataydorn, P., Oonsombat, P., 1993. Dog-bite injuries at a Bangkok teaching hospital. Acta Trop. 55, 249-255.
4. CDC, 1991. Recommendations of the immunization practices advisory committee. Rabies Prevention, United States, 1991. MMWR 40, 1-19 (1991).
5. Chutivongse, S., Wilde, H., Fishbein, B., Baer, G., Hemachudha, T., 1991. One-Year study of the 2-1-1 intramuscular post-exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9, 573-576.
6. Chutivongse, S., Wilde, H., Benjavongkulchai, M., Chomckey, P., Punthawong, S., 1995. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin. Infect. Dis. 20, 818-820.
7. Dean, D., Baer, G., 1963. Studies on the local treatment of rabies infected wounds. Bull. Who 28, 477-483.
8. Ho, M., Silamut, K., White, N., Karbwang, J., Looareesuwan, S., Phillips, R.E., Warell, D.A., 1990. Pharmacokinetics of three commercial antivenoms in patients envenomed by the malayan pit viper, colloselasma rhodostoma in Thailand. Am. J. Trop. Med. Hyg. 42, 260-266.
9. Khawplod, P., Wilde, H., Chomckey, P., Benjavongkulchai, M., Yenmuang, W., Chaiyabutr, N., Sitprija, V., 1996. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine 14, 389-391.
10. Meslin, F.X., 1994. Actualité sur la lutte contre la rage humaine et la vaccination antirabique. Cahier Santé 4, 203-204.
11. ™). Results from animal and human studies. Abstracts of the Seventeenth International Cong. Eur. Ass. Pois. Cent. and Clin. Toxicol., Marseille, France, pp. 91.
12. Strady, A., Lang, J., Rotivel, Y., Jaussaud, R., Fritzell, C., Tsiang, H., 1996. L'immuno-prophylaxie de la rage: actualisation des recommendations. Presse Med. 25, 1023-1027.
13. Tantawichien, T., Benjavongkulchai, M., Wilde, X., Jaijaroensup, W., Siakasem, A., Chareonwai, S., Yountong, C., Sitprija, V., 1995. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin. Infect. Dis. 21, 660-662.
14. WHO, 1989. Adverse Reaction Dictionary. Uppsala, Sweden.
15. WHO, 1992. Expert Committee on Rabies. Eighth report. Who Tech. Rep. Ser. 824, 1-84.
16. WHO, 1995. Consultation on intradermal application of human rabies vaccines. Geneva 13-14 March 1995. Weekly Epidemiological Record 47, 336-337.
17. WHO, 1996. WHO recommendations on rabies post-exposure treatment and the correct technique of interdermal immunization against rabies. WHO/EMC/ZOO.96.
18. Wilde, H., Chutivongse, S., 1990. Equine rabies immune globulin: a product with an undeserved poor reputation. Am. J. Trop. Med. Hyg. 42 (2), 175-178.
19. Wilde, H., Chomckey, P., Prakongsri, S., Punyaratabandhy, P., Chutivongse, S., 1989a. Adverse effects of equine rabies immune globulins. Vaccine 10, 10-11.
20. Wilde, H., Choomkasien, P., Hemachudha, T., Supich, C., Chutivongse, S., 1989b. Failure of rabies postexposure treatment in Thailand. Vaccine 7, 49-52.
21. Wilde, H., Sirikawin, S., Sabchareon, A., Kingnate, D., Tantawichien, T., Harischandra, P., et al., 1996a. Failure of postexposure treatment of rabies in children. Clin. Infect. Dis. 22, 228-232.
22. Wilde, H., Thipkong, P., Phar, B., Sitprija, V., Chaiyabutr, N., 1996b. Heterologous antisera and antivenins are still essential biologicals: perspectives of a worldwide crisis. Ann. Intern. Med. 125, 233-236.